Lentivirus-Mediated Gene Expression
Department of Medicine, Addenbrooke's Hospital, University of Cambridge, UK. Methods in Molecular Biology
(Impact Factor: 1.29).
02/2007; 366:343-55. DOI: 10.1007/978-1-59745-030-0_20
Lentiviruses have the capacity to enter and integrate their genetic material into cells that are not dividing. This property is retained in vectors based on these agents. They can thus effect gene delivery to cells that are difficult to transduce such as cardiac myocytes in vitro and in vivo. They are also relatively efficient at entering dividing cells and can transduce stem cells and vascular endothelium. They have a substantial gene-carrying capacity of up to around 9 kb. They do not trigger an inflammatory response and are thus useful when proinflammatory agents are undesirable, such as in transplantation. Their ease of cloning and well-understood molecular biology have made them highly suitable for gene delivery to the heart.
Available from: PubMed Central
- "The more recent two or three plasmid systems have increased the safety profile of lentiviral-based vectors but concerns remain regarding the possibility of recombination events producing a replication competent virus . However, the capacity of these vectors, of approximately 9 kb, makes them a very attractive option for future gene therapy research . "
[Show abstract] [Hide abstract]
ABSTRACT: Current pharmacological and surgical treatments for Parkinson's disease offer symptomatic improvements to those suffering from this incurable degenerative neurological disorder, but none of these has convincingly shown effects on disease progression. Novel approaches based on gene therapy have several potential advantages over conventional treatment modalities. These could be used to provide more consistent dopamine supplementation, potentially providing superior symptomatic relief with fewer side effects. More radically, gene therapy could be used to correct the imbalances in basal ganglia circuitry associated with the symptoms of Parkinson's disease, or to preserve or restore dopaminergic neurons lost during the disease process itself. The latter neuroprotective approach is the most exciting, as it could theoretically be disease modifying rather than simply symptom alleviating. Gene therapy agents using these approaches are currently making the transition from the laboratory to the bedside. This paper summarises the theoretical approaches to gene therapy for Parkinson's disease and the findings of clinical trials in this rapidly changing field.
03/2012; 2012:757305. DOI:10.1155/2012/757305
Available from: Jonathan M Hazlehurst
- "Further specificity can be given through the use of the human glial fibrillary acidic promoter (hGFAP) or neuron-specific enolase promoter (rNSE), giving glial or neuronal specificities respectively (Jakobsson 2006). This class of vectors certain several advantages, including a relatively large capacity for cloned genes (approximately nine kilobases) (Zhao 2007), but concerns relate to the possibility of recombination events, producing replication-competent virus. The use of two or three plasmid based transfection systems, in which the capsid assembly genes are genetically isolated has increased the safety profile of this class of vectors (Zufferey 1997) and this class looks particularly promising for future studies. "
Towards New Therapies for Parkinson's Disease, 11/2011; , ISBN: 978-953-307-463-4
[Show abstract] [Hide abstract]
ABSTRACT: Despite advances in surgery, radiotherapy, and the incorporation of novel systemic agents into treatment, long-term outcomes of patients with head and neck cancer remain unsatisfactory. The growing understanding of head and neck cancer biology suggests that targeting molecular events governing carcinogenesis or tumor progression may provide novel therapeutic approaches for head and neck cancer. Squamous cell carcinoma of the head and neck (SCCHN) is characterized by locoregional spread and is clinically accessible, making it an attractive target for intratumoral gene therapy, a potentially efficacious experimental treatment. Systemic delivery of gene therapy may be also possible, albeit with several limitations. In this review we will discuss the rationale, delivery methods, and accumulated clinical data with cancer gene therapy in SCCHN.
Current Gene Therapy 01/2008; 7(6):446-57. DOI:10.2174/156652307782793487 · 2.54 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.